Cost–effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer

References

• Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer. 2015;51(9):1164–1187.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65(2):467–479.
   PubMed Web of Science ®Google Scholar
• Mottel N, Bellmunt J, Briers E, et al. Guidelines on prostate cancer. In: European Association of Urology (EAU) Guidelines, edition presented at the 30th Annual EAU Congress; 2015 Mar 20–24; Madrid: EAU. ISBN 978-90-79754-80-9.
   Google Scholar
• Smith MR, Cook R, Lee KA, et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant non-metastatic prostate cancer. Cancer. 2011;117:2077–2085.
   PubMed Web of Science ®Google Scholar
• Papatsoris AG, Karamouzis M, Papavassiliou AG. Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Curr Med Chem. 2005;12:277–296.
   PubMed Web of Science ®Google Scholar
• Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–692.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Denosumab (Xgeva, Amgen) approval for the prevention of skeletal-related events in patients with bone metastases from solid tumors. [updated 2013 Jul 2; cited 2015 Apr 11]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/125320s007ltr.pdf
   Google Scholar
• Dellis A, Papatsoris AG. The economics of abiraterone acetate for castration-resistant prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):175–179.
   PubMed Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–342.
   PubMed Web of Science ®Google Scholar
• Reid IR, Miller PD, Brown JP, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010;25:2256–2265.
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Coleman R, et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a global phase 3, randomised, placebo-controlled trial. Lancet. 2012;379:39–46.
   PubMed Web of Science ®Google Scholar
• Peddi P, Lopez-Olivo MA, Pratt GR, et al. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2013;39:97–104.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration resistant prostate cancer: a randomized double-blind study. Lancet. 2011;377:813–822.
   PubMed Web of Science ®Google Scholar
• Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48:3082–3092.
   PubMed Web of Science ®Google Scholar
• Dellis A, Papatsoris AG. Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancer. Expert Opin Biol Ther. 2014;14:7–10.
   PubMed Web of Science ®Google Scholar
• Amgen. XGEVA(TM) (Denosumab) significantly improved bone metastasis-free survival in men with prostate cancer. Amgen Press release; 2010 [cited 2015 Jul 26. Available from: http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2010&releaseID=1507379.
   Google Scholar
• Sorensen S, Ellis L, Wu Y, et al. Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. J Manag Care Pharm. 2013;19:799–808.
   PubMed Web of Science ®Google Scholar
• Luengo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14:1165–1174.
   PubMed Web of Science ®Google Scholar
• Hart W, Nazir J, Baskin-Bey E. An incidence model of the cost of advanced prostate cancer in Spain. J Med Econ. 2014;17:125–131.
   PubMedGoogle Scholar
• Hatoum HT, Crawford ED, Nielsen SK, et al. Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2013;13:251–259.
   PubMed Web of Science ®Google Scholar
• Piper NY, Kusada L, Lance R, et al. Adenocarcinoma of the prostate: an expensive way to die. Prostate Cancer Prostatic Dis. 2002;5:164–166.
   PubMed Web of Science ®Google Scholar
• Zeliadt SB, Penson DF. Pharmacoeconomics of available treatment options for metastatic prostate cancer. Pharmacoeconomics. 2007;25:309–327.
   PubMed Web of Science ®Google Scholar
• Dragomir A, Dinea D, Vanhuyse M, et al. Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. BMC Health Serv Res. 2014;14:252–265.
   PubMed Web of Science ®Google Scholar
• Vasani D, Josephson DY, Carmichael C, et al. Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. Maturitas. 2011;70:194–196.
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB. Unravelling the role of denosumab in prostate cancer. Lancet. 2011;377:785–786.
   PubMed Web of Science ®Google Scholar
• West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol. 2011;29:1095–1098.
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Carter JA, Kaura S, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. J Med Econ. 2013;16:19–29.
   PubMedGoogle Scholar
• Amgen. FDA approves Amgen’s XGEVA(TM) (Denosumab) for the prevention of skeletal-related events in patients with bone metastases from solid tumors. Amgen Press Release; 2010 [cited 2012 Mar 9]. Available from: http://www.amgen.com/media/ media_pr_detail.jsp? release ID=1498709.
   Google Scholar
• Drug topics red book … update. Montvale (NJ): Medical Economics; 2010. p. c1996–c2003. NLM ID: 9810530 [Serial]. ISSN:1546-7333 (Print); 1546-7333 (Linking).
   Google Scholar
• Ford J, Cummins E, Sharma P, et al. Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. Health Technol Assess. 2013;17:1–386.
   PubMed Web of Science ®Google Scholar
• Xie J, Namjoshi M, Wu EQ, et al. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm. 2011;17:621–643.
   PubMed Web of Science ®Google Scholar
• Rader M, Goessl C. Economic evaluation of denosumab compared with zoledronic acid in hormone- refractory prostate cancer patients with bone metastases. J Manag Care Pharm. 2012;18:74–75.
   PubMed Web of Science ®Google Scholar
• Stopeck A, Rader M, Henry D, et al. Cost–effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ. 2012;15:712–723.
   PubMedGoogle Scholar
• Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer. 2008;113:1438–1445.
   PubMed Web of Science ®Google Scholar
• Lothgran M, Ribnicsek E, Schmidt L, et al. Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland. Eur J Hosp Pharm. 2013;20:227–231.
   PubMedGoogle Scholar
• Froehner M, Holscher T, Hakenberg OW, et al. Treatment of bone metastases in urologic malignancies. Urol Int. 2014;93:249–256.
   PubMed Web of Science ®Google Scholar
• Saad F, Shore N, Van Poppel H, et al. Impact of bone-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015. DOI:10.1016/j.eururo.2015.04.032.
   Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–323.
   PubMed Web of Science ®Google Scholar
• Gartrell BA, Coleman R, Efstathiou E, et al. Metastatic prostate cancer and the bone: significance and therapeutic options. Eur Urol. 2015. DOI:10.1016/j.eururo.2015.06.039.
   Web of Science ®Google Scholar
• Parker C, Gillessen S, Heidenreich A, et al. on behalf of the ESMO guidelines committee et al. Ann Oncol. 2015;26(Suppl 5):v69–v77.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Prostate Cancer. Version 1 2015. [cited 2014 Jun 16]. Available from: http://www.nccn.org/patients/guidelines/prostate/files/assets/common/downloads/files/prostate.pdf.
   Google Scholar
• de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
   PubMed Web of Science ®Google Scholar
• Carter JA, Botteman MF. Health-economic review of zoledronic acid for the management of skeletal-related events in bone metastatic prostate cancer. Expert Rev Pharmacoecon Outcomes Res. 2012;12:425–437.
   PubMed Web of Science ®Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. ISPOR-SMDM modeling good research practices task force. State-transition modeling: a report of the ISPOR-SMDM modeling good research practices task force-3. Value Health. 2012;15:812–820.
   PubMed Web of Science ®Google Scholar
• Henk HJ, Kaura S. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan. J Med Econ. 2012;15:175–184.
   PubMedGoogle Scholar
• Sun L, Yu S. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases. A systematic review and meta-analysis. Am J Clin Oncol. 2013;36:399–403.
   PubMed Web of Science ®Google Scholar
• Smith MR, Coleman RE, Klotz L, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol. 2015;262:368–374.
   Web of Science ®Google Scholar